Industry Research by Koncept Analytics
Global PNH & aHUS Market: Industry Analysis & Outlook ----------------------------------------(2017-2021) October 2017
Global PNH and aHUS Market: Industry Analysis & Outlook (2017-2021)
1
Executive Summary PNH and aHUS, both are extremely rare and genetic diseases. Due to PNH, destruction of red blood cells of a person occur quite sooner than it should. It is an acquired hematopoietic stem cell disorder. Hematopoietic stem cells are developed in bone marrow and eventually turn into red blood cells, white blood cells and platelets. A person with PNH has some defected hematopoietic cells which create defective red blood cells. These defective cells are highly susceptible to premature destruction by the complement system. aHUS is a disorders in which blood clots are formed in small blood vessels throughout the body. TMA can lead to heart stroke, attack, kidney failure and death. Soliris is the only drug treatment available in the market for treating these diseases. Regionally, Europe held the largest share in the global PNH drug market and the U.S. dominated the global aHUS drug market, supported by favorable reimbursement policies In terms of patient population, Asia-pacific region had the highest number of PNH and aHUS patients. With the increasing technological advancements in diagnosis techniques of PNH and aHUS, the number of diagnosed patients is likely to grow globally. The global PNH and aHUS market is expected to grow in future due to prolonged orphan drug market exclusivity, attractive orphan drug policies, increasing pharmaceutical R&D expenditure, rising health care expenditure. Key trends of this market includes progressing drugs under pipeline, increasing prevalence of blood and bone marrow related disorders and favorable reimbursement policies. However, there are some factors which can hinder the market growth including high costs of drugs and associated risks. The report “Global PNH and aHUS Market: Industry Analysis & Outlook (2017-2021)� by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and AsiaPacific region along with the global market. The report profiles the key players of the market including Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc, Omeros Corporation and RA Pharmaceuticals.
Global PNH and aHUS Market: Industry Analysis & Outlook (2017-2021)
2
Increasing prevalence of blood and bone marrow related disorders is expected to boost the global PNH patient population…
Thousand
Global PNH Patient Population Forecast (2016-2021) • Global PNH patient population is expected to reach ..thousand in the year 2021, increasing from ..thousand in the year 2016 at a CAGR of ..% for period spanning 2016-2021. • In the year 2021, global PNH drug market value is expected to reach US$.. million, increasing from US$.. million in 2016, growing at a CAGR of ..% for period spanning 2016-2021.
2016
2017
2018
Total
2019
2020
2021
• In 2016, Europe held the largest share of ..% in global PNH drug market, followed by the U.S. with a share of .. %.
Diagnosed Patients Global PNH Drug Market Value by Region (2016)
US$ Million
Global PNH Drug Market Value Forecast (2016-2021)
2016
2017
2018 Soliris
2019
ALXN1210
2020
2021
Europe
The U.S.
Global PNH and aHUS Market: Industry Analysis & Outlook (2017-2021)
Asia-Pacific
ROW
3
Global aHUS market is likely to grow with increasing technological advancements in diagnosis methods and rising investments in research and development of aHUS drugs..
Thousand
Global aHUS Patient Population Forecast (2016-2021) • Global aHUS patient population is expected to reach … thousand in the year 2021, increasing from ..thousand in the year 2016 at a CAGR of ..% for period 20162021.. • In the year 2021, global aHUS drug market value is predicted to reach US$.. million, increasing from US$.. million in 2016, recording growth at a CAGR of ..% for period 2016-2021. 2016
2017
2018
2019
2020
2021
Total
• The U.S. held the largest share of ..% in the global aHUS drug market, followed by Europe with a share of .. % in 2016.
Newly Diagnosed Patients per Year Global aHUS Drug Market Value by Region (2016)
US$ Million
Global aHUS Drug Market Value Forecast (2016-2021)
2016
2017
2018 Soliris
2019
ALXN1210
2020
2021
The U.S.
Europe
Global PNH and aHUS Market: Industry Analysis & Outlook (2017-2021)
Asia-Pacific
ROW
4
Contact Us:
Disclaimer
This is a licensed product of Koncept Analytics. You cannot reproduce, publish, distribute, publicly display, sell or create other works from this report or use them in any way for commercial purpose without our prior permission. Further, you cannot copy this material, by any means (including electronic copies), for distribution to others unless you have purchased the corporate license of this report. We believe the sources are reliable, but Koncept Analytics does not warranty the accuracy or completeness of the data. The data presented in the report is updated at the publication date but is subject to change at subsequent releases. All possible efforts have been made to ensure accuracy of data. However, investors should not completely rely on the information given in this report and must make decisions based on their own investment strategy, risk management and capital adequacy.
For Report Purchase Click Below: http:// www.konceptanalytics.com/Researchreport/global-pnh-ahus-market-industry-analysis-outlook-2017-2021-26464.aspx Koncept Analytics CS-36, First Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T: +91-120-4130959 M: +91-9871694789 vikas@konceptanalytics.com www.konceptanalytics.com